- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
McKesson Corporation(MCK)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for MCK
11/13/2026: MCK (3-star) is a STRONG-BUY. BUY for 89 days. Simulated Profits (35.91%). Updated daily EoD!
McKesson Corporation is a leading healthcare services and wholesale pharmaceutical distribution company operating primarily in North America. The firm benefits from massive supply chain scale, a dominant position in high-margin specialty drug distribution, and robust technology platforms like CoverMyMeds. Its primary growth story centers on expanding specialty care logistics and tech-enabled biopharma services, offset by risks such as thin operating margins, customer concentration, and ongoing regulatory and drug-pricing scrutiny. The stock suits total-return and conservative investors seeking stable exposure to essential healthcare infrastructure, while market participants should monitor specialty segment growth and legislative drug pricing developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | While earnings growth has been solid due to specialty drug demand, the top-line growth rate reflects a mature wholesale distribution giant. |
| Momentum investor | Strong fit while signal remains positive | McKesson has frequently exhibited strong medium-term price momentum supported by consistent earnings beats and positive estimate revisions. |
| Value investor | Moderate fit | The stock often trades at reasonable price-to-earnings multiples relative to the broader market, though recent outperformance has compressed traditional deep-value appeal. |
| Dividend investor | Mixed fit | The company offers reliable dividend growth and consistent buybacks, though its modest dividend yield appeals more to total-return seekers than high-yield income investors. |
| Low-risk investor | Strong fit | As an essential healthcare staple with stable demand profiles and defensive characteristics, it fits conservative portfolios well. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Low | The stock generally displays lower volatility than high-growth technology sectors due to its defensive business model. |
| Valuation risk | Medium | Strong historical outperformance means the stock trades at higher multiples than its historical average, leaving less room for earnings misses. |
| Competition risk (oligopolistic distributor competition) | Medium | Intense margin pressure from major peers like Cencora and Cardinal Health limits pricing power in core distribution. |
| Business quality | Strong | McKesson's deep economic moat as an indispensable healthcare supply chain backbone underpins high franchise quality. |
| Dividend income | Medium | Payouts are secure and growing, but the low initial dividend yield limits immediate cash income generation. |
| Execution risk | Medium | Successful execution in scaling specialty distribution and tech solutions is vital to maintaining double-digit EPS growth. |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 127.33B USD | Price to earnings Ratio 28.44 | 1Y Target Price 1144.29 |
Price to earnings Ratio 28.44 | 1Y Target Price 1144.29 | ||
Volume (30-day avg) 703.8K shares | Beta 0.28 | 52 Weeks Range 722.11 - 1121.50 | Updated Date 11/15/2026 |
52 Weeks Range 722.11 - 1121.50 | Updated Date 11/15/2026 | ||
Dividends yield (FY) 0.32% | Basic EPS (TTM) 38.77 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.7%
- Active BUY / eligible
- 69 / 110
- 30-Day BUY Count Change
- +30
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Medical Distribution
- BUY participation
- 100.0%
- Active BUY / eligible
- 3 / 3
- 30-Day BUY Count Change
- +2
Eligible universe: 3 stocks.
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit 50.31% | Avg. Invested days 51 | Today’s Advisory Strong Buy |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| US Pharmaceutical segment | Wholesale distribution of brand-name, generic, specialty, and over-the-counter pharmaceutical products. | This is the primary revenue engine, generating massive sales volume but operating on very thin percentage margins. |
| Prescription Technology Solutions (RxTS) | Platforms like CoverMyMeds that connect pharmacies, providers, and payers to streamline medication access and affordability. | A high-margin technology growth driver that enhances profitability beyond traditional distribution. |
| Medical-Surgical Solutions segment | Distribution of medical supplies, equipment, and lab products to alternate-site healthcare providers. | Provides stable, recurring revenue streams from physician offices and outpatient care centers. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-04 | When After Market | Estimate 10.69 | Actual 11.68 |
Profitability
Profit Margin 1.12% | Operating Margin (TTM) 1.59% |
Management Effectiveness
Return on Assets (TTM) 4.72% | Return on Equity (TTM) - |
Valuation
Trailing PE 28.44 | Forward PE 23.98 | Enterprise Value 131.96B | Price to Sales(TTM) 0.3 |
Enterprise Value 131.96B | Price to Sales(TTM) 0.3 | ||
Enterprise Value to Revenue 0.32 | Enterprise Value to EBITDA 17.12 | Shares Outstanding 115.46M | Shares Floating 115.26M |
Shares Outstanding 115.46M | Shares Floating 115.26M | ||
Percent Insiders 0.36 | Percent Institutions 90.82 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

